Physician profile
Philip Pancari
NPI 1285953158
$69,695.77
in general payments reported to CMS, 2019-2025
27 companies · $68K in 2025
The $68K reported for 2025 was more than what 96% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.00 · 2020: $15.44 · 2021: $23.36 · 2022: $255 · 2023: $458 · 2024: $853 · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Travel and Lodging: $7,289 · Food and Beverage: $3,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,985.00 |
| Travel and Lodging | $7,289.44 |
| Food and Beverage | $3,033.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $67,147.18 | 2025 | |
| Genmab U.S., INC. | $356.76 | 2023-2025 | Epkinly |
| Celgene Corporation | $309.22 | 2019-2025 | Breyanzi, Abecma |
| Daiichi Sankyo INC. | $306.12 | 2022-2025 | Vanflyta |
| Amgen INC. | $287.11 | 2022-2025 | Blincyto, Blincyto |
| Incyte Corporation | $243.24 | 2023-2025 | Jakafi, Monjuvi, Monjuvi |
| Kite Pharma, INC. | $154.35 | 2024-2025 | Yescarta |
| Janssen Biotech, INC. | $146.21 | 2025 | Rybrevant, Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $134.06 | 2024-2025 | Iclusig |
| Seagen INC. | $132.00 | 2023 | Adcetris |
| Tempus Ai, INC | $99.71 | 2024 | Xt Cdx |
| Legend Biotech USA INC. | $93.13 | 2025 | Carvykti |
| Novartis Pharmaceuticals Corporation | $60.60 | 2022-2024 | |
| Abbvie INC. | $53.60 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.83 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $18.18 | 2025 | |
| Astellas Pharma US INC | $16.65 | 2023 | Padcev |
| Pfizer INC. | $15.89 | 2023 | |
| Sumitomo Pharma America, INC. | $15.78 | 2023 | Orgovyx |
| Spectrum Pharmaceuticals INC. | $15.70 | 2023 | Rolvedon |
| Verastem, INC. | $15.44 | 2020 | |
| Agios Pharmaceuticals, INC. | $14.89 | 2023 | Pyrukynd |
| Genentech USA, INC. | $12.76 | 2023 | Lunsumio, Columvi |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Foundation Medicine, INC. | $11.44 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Pancari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.